表紙:輸血診断の世界市場予測(2022年~2027年)
市場調査レポート
商品コード
1071428

輸血診断の世界市場予測(2022年~2027年)

Global Blood Transfusion Diagnostics Market - Forecasts from 2022 to 2027

出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 124 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.18円
輸血診断の世界市場予測(2022年~2027年)
出版日: 2022年03月09日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 124 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の輸血診断の市場規模は、2020年は24億5,100万米ドルで、予測期間中に6.28%のCAGRで成長し、2027年には37億5,500万米ドルに達すると予測されています。

当レポートでは、世界の輸血診断市場を調査しており、市場の概要、市場規模や予測、動向、成長要因および抑制要因、タイプ・技術・エンドユーザー・地域別の分析、および競合情勢などを提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション

第2章 調査手法

  • 調査データ
  • 前提条件

第3章 エグゼクティブサマリー

  • 調査のハイライト

第4章 市場力学

  • 市場促進要因
  • 市場抑制要因
  • ポーターのファイブフォース分析
    • 供給側の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 業界における競合情勢
  • 業界のバリューチェーン分析

第5章 世界の輸血診断市場分析:タイプ別

  • イントロダクション
  • 機器
  • キット・試薬

第6章 世界の輸血診断市場分析:技術別

  • イントロダクション
  • ELISA
  • ウエスタンブロッティング
  • 核酸増幅
  • その他

第7章 世界の輸血診断市場分析:エンドユーザー別

  • イントロダクション
  • 病院とクリニック
  • 診断ラボ
  • 血液バンク

第8章 世界の輸血診断市場分析:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 欧州
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • その他
  • 中東とアフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • タイ
    • 台湾
    • インドネシア
    • その他

第9章 競合環境と分析

  • 主要企業と戦略分析
  • 新興企業と市場の収益性
  • 合併、買収、合意、およびコラボレーション
  • ベンダー競争力マトリックス

第10章 企業プロファイル

  • Quotient Ltd.
  • BAG Healthcare
  • Abbott
  • Immucor
  • Diasorin SPA
  • Bio-Rad Laboratories Inc.
  • Grifols S.A.
  • F. Hoffmann La Roche Ltd.
  • Beckman Coulter Inc.
  • DIAGAST
目次
Product Code: KSI061611612

The global blood transfusion diagnostics market was valued at US$2.451 billion in 2020 and is expected to grow at a CAGR of 6.28% over the forecast period to reach a total market size of US$3.755 billion by 2027.

Blood transfusion diagnostics refers to testing conducted on blood and blood components prior to transfusion to patients. To avoid adverse reactions or infection transmission, each blood unit must be checked for blood group type and disease screening. It is an essential component of transfusion treatment since it offers vital information to healthcare practitioners and validates the compatibility of donor and recipient blood samples. Red blood cells are the most frequently transfused blood products. Molecular blood group diagnosis is one of the transfusion diagnostics. For patients who have antibodies against clinically relevant, uncommon, or weak antigens, molecular blood group diagnosis allows for safer blood storage and on-demand supplies.

Developing and underdeveloped countries lack proper blood banks, medical equipment required for blood transfusion, adequate conditions for blood storage, and a limited supply of blood in response to high demand. Hospitals lack the necessary amenities to deliver hygienic and safe transfusions. Thus, the escalating burden of chronic disorders and the rising need for donor screening are boosting the market's growth. Furthermore, the rising need for transfusions because of trauma, car accidents, and surgical procedures is favourably influencing the market.

The emergence of advanced molecular platforms by market leaders accelerates the transition from manual testing and equipment to semi-automated and fully automated devices. These automated systems have been critical in detecting transfusion transmissible infections (TTIs) in blood samples and can accurately remove human error throughout the transfusion procedure.

During the forecast period, North America is expected to be the largest regional market for the global blood transfusion diagnostics market. This dominance can be attributed to increased acceptance of the blood transfusion procedure, increased public awareness regarding blood donations, and developed healthcare infrastructure. According to data released by the National Center for Biotechnology Information, over 15 million blood units are transfused in the United States each year, with an estimated 85 million units transfused globally.

Growth Factors

  • Blood and blood components are in high demand.

The rising prevalence of blood-related conditions such as haemophilia, cancer, thrombocytopenia, and others, as well as chronic kidney disease (CKD), has increased the demand for blood transfusions. According to World Kidney Day estimates, about 850 million individuals worldwide will be suffering from kidney diseases in 2020. In addition, one out of every ten individuals has chronic kidney disease (CKD), which is predicted to become the sixth leading cause of death by the end of 2040. Furthermore, the growing number of patients suffering from anaemia necessitates red blood cell transfusion for treatment, which is further driving up the demand for blood transfusion diagnostics. The World Health Organization (WHO) estimates that anaemia affects around 1.62 billion people worldwide. This, together with increased awareness regarding blood safety from infectious diseases through various initiatives in developed and developing nations, is driving up demand for blood screening tests and other diagnostic instruments.

Restraints:

  • The high cost of instruments and a lack of infrastructure

Despite the rising prevalence of chronic blood disorders and increased demand for blood transfusions, several issues are impeding the market's growth. One of the causes is a lack of investment in healthcare infrastructure and strict government policies, particularly in developing nations when compared to developed countries. Furthermore, the high cost of tests, instruments, and reagents, along with a shortage of qualified professionals to handle automated diagnostic solutions, is one of the factors restraining the growth of the blood transfusion diagnostics market during the forecast period.

The Impact of COVID-19 on the Blood Transfusion Diagnostics Market:

The COVID-19 pandemic had a detrimental impact on the market. The outbreak reduced the number of voluntary blood donors and affected the global supply chain of medical equipment. Some of the primary problems encountered by blood banks and hospitals during the crisis included decreased donor inflow, a lack of staff personnel, a scarcity of blood units, and public anxiety over transfusion-transmitted COVID-19. According to the American Red Cross, the organisation lost around 46,000 blood unit donations due to the pandemic. In addition, a few donor locations saw a significant decrease in blood donations due to lockdowns and suspension of blood drives. However, by the third quarter of 2020, most countries had lifted lockdown and stay-at-home rules, resulting in an increase in blood donations and transfusion operations across all blood centres.

Competitive insight:

Officials from the State Blood Transfusion Council (SBTC) reported in September 2021 that supplies in Maharashtra blood banks would barely last a week. This drop was attributed to a decrease in blood donation camps, reduced donor footfall owing to the pandemic, and the closure of offices and institutions in the state.

The American Red Cross started a new nationwide initiative in September 2021 to reach out to more black blood donors in order to aid patients with sickle cell disease and improve health outcomes. Blood donations from individuals of the same race or ethnicity as well as blood type are the most reliable option to treat sickle cell patients.

Segmentation:

  • By Type

Instruments

Kits & Reagents

  • By Technology

ELISA

Western Blotting

Nucleic Acid Amplification

Others

  • By End-User

Hospitals & Clinics

Diagnostic Labs

Blood Banks

  • By Geography

North America

  • United States
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • France
  • Germany
  • Italy
  • Others

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Blood Transfusion Diagnostics Market Analysis, By Type

  • 5.1. Introduction
  • 5.2. Instruments
  • 5.3. Kits & Reagents

6. Global Blood Transfusion Diagnostics Market Analysis, By Technology

  • 6.1. Introduction
  • 6.2. ELISA
  • 6.3. Western Blotting
  • 6.4. Nucleic Acid Amplification
  • 6.5. Others

7. Global Blood Transfusion Diagnostics Market Analysis, By End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Diagnostic Labs
  • 7.4. Blood Banks

8. Global Blood Transfusion Diagnostics Market Analysis, By Geography 

  • 8.1.  Introduction
  • 8.2.  North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. France
    • 8.4.3. Germany
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Thailand
    • 8.6.5. Taiwan
    • 8.6.6. Indonesia
    • 8.6.7. Others

9.  Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2.  Emerging Players and Market Lucrativenessness
  • 9.3.  Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4.  Vendor Competitiveness Matrix

10. Company Profiles

  • 10.1. Quotient Ltd.
  • 10.2. BAG Healthcare
  • 10.3. Abbott
  • 10.4. Immucor
  • 10.5. Diasorin SPA
  • 10.6. Bio-Rad Laboratories Inc.
  • 10.7. Grifols S.A.
  • 10.8. F. Hoffmann La Roche Ltd.
  • 10.9. Beckman Coulter Inc.
  • 10.10. DIAGAST